Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Promyelocytic leukemia protein PML inhibits Nur77-mediated transcription through specific functional interactions

Abstract

The promyelocytic leukemia protein PML is a tumor and growth suppressor and plays an important role in a multiple pathways of apoptosis and regulation of cell cycle progression. Our previous studies and others also documented a role of PML in transcriptional regulation through its association with transcription coactivator CBP and transcription corepressor HDAC. Here, we showed that PML is a potent transcriptional repressor of Nur77, an orphan receptor and a member of the steroid receptor superfamily of proteins. We found that PML represses Nur77-mediated transactivation through a physical and functional interaction between the two proteins. PML interacts with Nur-77 in vitro in a GST-pull down assay and in vivo by coimmunoprecipitation assay. PML/Nur77 colocalized in vivo in a double immunofluorescent staining and confocal microscopic analysis. Our study further showed that the coiled–coil domain of PML interacts with the DNA-binding domain of Nur77 (amino acids 267–332). Electrophoretic mobility shift assay demonstrated that PML interferes with Nur77 DNA binding in a dose-dependent manner. This study indicates that PML interacts with the DNA-binding domain of Nur77 and represses transcription by preventing it from binding to the target promoter. This study supports a role of PML/Nur77 interaction in regulating cell growth and apoptosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Amsen D, Calvo CR, Osborne BA, Kruisbeek AM . 1999 Proc. Natl. Acad. Sci. USA 96: 622–627

  • Boisvert F-M, Hendzel MJ, Bazett-Jone DP . 2000 J. Cell Biol. 148: 282–292

  • Boisvert F-M, Kruhlak MJ, Box AK, Hendzel MJ, Bazett-Jones DP . 2001 J. Cell Biol. 152: 1099–1106

  • Calnan BJ, Szychowski S, Chan KM, Cado D, Winoto A . 1995 Immunity 3: 273–282

  • Doucas V, Evans RM . 1999 Proc. Natl. Acad. Sci. USA 96: 2633–2638

  • Doucas V, Tini M, Egan DA, Evans RM . 1999 Proc. Natl. Acad. Sci. USA 96: 2627–2632

  • Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN, Solomon E, de The H, Hay RT, Freemont PS . 1999 J. Cell Sci. 112: 381–393

  • Enmark E, Gustafssan JA . 1996 Mol. Endocrinol. 10: 1293–1307

  • Everett RD . 2001 Oncogene 20: 7266–7273

  • Ferbeyre G, Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW . 2000 Genes Dev. 14: 2015–2027

  • Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, Pandolfi PP, Will H, Schneider C, DelSal G . 2000 EMBO J. 22: 6186–6195

  • Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, Pandolfi PP . 2000 Nat. Cell Biol. 2: 730–736

  • Hazel TG, Nathans D, Lau LF . 1988 Proc. Natl. Acad. Sci. USA 85: 8444–8449

  • Herschman HR . 1991 Ann. Rev. Biochem. 60: 281–319

  • Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T, Yeh ET, Strauss II JF, Maul GG . 1999 J. Cell Biol. 147: 221–234

  • Kastner P, Perez A, Lutz Y, Rochette E, Gaube MP, Durand B, Lanotte M, Berger R, Chambon P . 1992 EMBO J. 11: 629–642

  • Kamitani T, Kito K, Nyuyen HP, Wada H, Fukuda-Kamitani T, Yeh ET . 1998 J. Biol. Chem. 273: 26675–26682

  • Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, Shinagawa T, Ichikawa-Iwata E, Zhong S, Pandolfi PP, Ishii S . 2001 Mol. Cell 7: 1233–1243

  • LaMorte VJ, Dyck JA, Ochs RL, Evans RM . 1998 Proc. Natl. Acad. Sci. USA 95: 4991–4996

  • Le XF, Yang P, Chang KS . 1996 J. Biol. Chem. 271: 130–135

  • Le XF, Vallian S, Mu ZM, Hung MC, Chang KS . 1998 Oncogene 16: 1839–1849

  • Li H, Kolluri KS, Gu J, Dawson MI, Cao X, Hobbs PD, Lin B, Chen G, Lu J-S, Lin F, Xie Z, Fontana JA, Reed JC, Zhang X-K . 2000a Science 289: 1159–1164

  • Li H, Leo C, Zhu J, Wu XY, O'Neil J, Park EJ, Chen JD . 2000b Mol. Cell. Biol. 20: 1784–1796

  • Lin RJ, Sternsdorf T, Tini M, Evans RM . 2001 Oncogene 20: 7204–7215

  • Liu JH, Mu ZM, Chang KS . 1995 J. Exp. Med. 181: 1965–1973

  • Liu ZG, Smith SW, McLaughlin KA, Schwartz LM, Osborne BA . 1994 Nature 367: 281–284

  • Maul GG . 1998 Bioessays 20: 660–667

  • Melnick A, Licht JD . 1999 Blood 93: 3167–3215

  • Milbrandt J . 1988 Neuron 1: 183–188

  • Mirzoeva OK, Petrini JHJ . 2001 Mol. Cell. Biol. 21: 281–288

  • Mu ZM, Chin KV, Liu JH, Lozano G, Chang KS . 1994 Mol. Cell. Biol. 14: 6858–6867

  • Mu ZM, Le XF, Vallian S, Glassman AB, Chang KS . 1997 Carcinogenesis 18: 2063–2069

  • Nakai A, Kartha S, Sakurai A, Toback FG, DeGroot LJ . 1990 Mol. Endocrinol. 4: 1438–1443

  • Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG . 2000 Nature 406: 207–210

  • Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H . 1998 Nature Genet. 20: 259–265

  • Seeler J-S, Dejean A . 2001 Oncogene 20: 7243–7249

  • Tsuzuki S, Towatari M, Saito H, Enver T . 2000 Mol. Cell. Biol. 20: 6276–6286

  • Uemura H, Chang C . 1998 Endocrinology 139: 2329–2334

  • Vallian S, Gaken AJ, Gingold EB, Kouzarides T, Chang KS, Farzaneh F . 1998a Oncogene 90: 3265–3269

  • Vallian S, Gaken JA, Trayner ID, Gingold EB, Kourizarides T, Chang KS, Farzaneh F . 1997 Exp. Cell. Res. 237: 371–382

  • Vallian S, Chin KV, Chang KS . 1998b Mol. Cell. Biol. 18: 7147–5156

  • Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Gordon-Cardo C, Grosweld F, Pandolfi PP . 1998 Science 279: 1547–1551

  • Weih F, Ryseck RP, Chen L, Brovo R . 1996 Proc. Natl. Acad. Sci. USA 93: 5533–5538

  • Wilson TE, Mouw AR, Weaver CA, Milbrandt J, Parker KL . 1993 Mol. Cell. Biol. 13: 861–868

  • Woronicz JD, Cainan B, Ngo V, Winoto A . 1994 Nature 367: 227–281

  • Wu WS, Vallian S, Seto E, Yang WM, Edmondson D, Roth S, Chang KS . 2001 Mol. Cell. Biol. 21: 2259–2268

  • Zhong S, Delva L, Tachez C, Cenciarelli C, Gandini D, Zhang H, Kalantry S, Freedman LP, Pandolfi PP . 1999 Nat. Genet. 23: 287–295

  • Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP . 2000 Blood 95: 2748–2752

Download references

Acknowledgements

DNA sequencing facility and Confocal microscopic analysis were supported by a research grant CA-16627 from the National Cancer Institute. This study was supported by a grant from the National Institute of Health CA-55577 to KS Chang.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kun-Sang Chang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, WS., Xu, ZX., Ran, R. et al. Promyelocytic leukemia protein PML inhibits Nur77-mediated transcription through specific functional interactions. Oncogene 21, 3925–3933 (2002). https://doi.org/10.1038/sj.onc.1205491

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205491

Keywords

This article is cited by

Search

Quick links